Tumor‐specific factors, such as the immune microenvironment, immune evasion mechanisms, tumor aneuploidy, and the presence of specific mutations (e.g., BRCA1/2, PTEN, PBRM1, or JAK1), all contribute to ICI treatment outcomes,[48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59] highlighting the necessity for a more comprehensive analysis of the TME. This evidence concerns the gene JAK1 and neoplasm.